[Hormone therapy for uterine corpus cancer--introduction].
Sugiyama
Toru
T
Department of Obstetrics & Gynecology, Iwate Medical University School of Medicine.
Izutsu
Toshihiko
T
D000077713:17 alpha-Hydroxyprogesterone Caproate; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D004967:Estrogens / Q000502:physiology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006908:Hydroxyprogesterones / Q000009:adverse effects / Q000627:therapeutic use; D016729:Leuprolide / Q000009:adverse effects / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects / Q000627:therapeutic use; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D011980:Receptors, Progesterone / Q000502:physiology; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D006908:Hydroxyprogesterones; D011980:Receptors, Progesterone; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D000077713:17 alpha-Hydroxyprogesterone Caproate; D007987:Gonadotropin-Releasing Hormone; D020849:Raloxifene Hydrochloride; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide